Artelo Biosciences Inc Financials
This page shows Artelo Biosciences Inc (ARTL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Artelo’s numbers show a cash-consuming operating model now reliant on outside financing as the balance sheet contracts over time.
From FY2023 to FY2025, operating cash outflow barely moved, holding near-$8.2M and-$8.5M . Yet total assets fell from$13.0M to$2.8M , which means the business kept consuming capital at roughly the same pace while the balance sheet underneath it became far thinner.
FY2025’s financing inflow added
Balance-sheet pressure is now visible in both short-term liquidity and capital structure: current assets were
Financial Health Signals
Artelo Biosciences Inc does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Artelo Biosciences Inc passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Artelo Biosciences Inc reported a net loss of $12.9M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Artelo Biosciences Inc reported an operating loss of $11.4M against $194K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Artelo Biosciences Inc reported -$12.9M in net income in fiscal year 2025. This represents a decrease of 31.1% from the prior year.
Artelo Biosciences Inc earned -$37.75 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Artelo Biosciences Inc held $600K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Artelo Biosciences Inc invested $5.4M in research and development in fiscal year 2025. This represents a decrease of 9.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
ARTL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | N/A | $5.4M-9.5% | $6.0M+5.2% | $5.7M+31.7% | $4.3M+14.3% | $3.8M+97.2% | $1.9M+75.7% | $1.1M-12.6% | $1.2M | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | $6.0M+45.3% | $4.1M-2.8% | $4.2M-29.0% | $6.0M+5.9% | $5.6M+103.6% | $2.8M+190.5% | $952K+87.4% | $508K+358.5% | $111K+14642.7% | $752+47.7% | $509-88.1% | $4K |
| Operating Income | N/A | -$11.4M-12.8% | -$10.1M-1.8% | -$9.9M+3.5% | -$10.3M-9.2% | -$9.4M-101.0% | -$4.7M-46.0% | -$3.2M | N/A | -$233K | N/A | -$15K+0.2% | -$15K |
| Interest Expense | N/A | $194K | $0 | $0-100.0% | $5K | $0 | N/A | N/A | N/A | $2K | N/A | N/A | N/A |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | N/A | N/A |
| Net Income | N/A | -$12.9M-31.1% | -$9.8M-5.8% | -$9.3M+7.9% | -$10.1M-7.2% | -$9.4M-102.1% | -$4.7M-114.3% | -$2.2M | N/A | -$235K | N/A | -$15K+0.2% | -$15K |
| EPS (Diluted) | — | -$37.75 | -$54.89 | -$18.80 | N/A | N/A | N/A | -$1.46 | -$1.84 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ARTL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.8M-40.4% | $4.7M-64.0% | $13.0M-36.1% | $20.4M-27.7% | $28.3M+545.6% | $4.4M-32.5% | $6.5M+1532.9% | $397K-30.9% | $574K+15896.5% | $4K-78.9% | $17K+15.6% | $15K |
| Current Assets | $695K-72.8% | $2.6M-76.7% | $11.0M-40.1% | $18.3M-25.5% | $24.6M+953.0% | $2.3M-47.4% | $4.4M+1020.6% | $396K-31.0% | $574K+15896.5% | $4K-78.9% | $17K+15.6% | $15K |
| Cash & Equivalents | $600K-74.3% | $2.3M-16.9% | $2.8M-59.1% | $6.9M-43.4% | $12.2M+467.8% | $2.1M-51.6% | $4.4M+1211.1% | $337K-41.1% | $573K+15854.7% | $4K-78.9% | $17K+15.6% | $15K |
| Total Liabilities | $4.1M+121.2% | $1.8M+42.6% | $1.3M+26.4% | $1.0M-5.8% | $1.1M+116.4% | $501K-51.0% | $1.0M+92.3% | $532K+1707.1% | $29K+69.3% | $17K+900.0% | $2K | $0 |
| Current Liabilities | $4.0M+128.2% | $1.8M+37.3% | $1.3M+29.4% | $998K-2.8% | $1.0M+105.0% | $501K-51.0% | $1.0M+92.0% | $532K+1707.1% | $29K+69.3% | $17K+900.0% | $2K | N/A |
| Total Equity | -$1.3M-144.5% | $2.9M-75.7% | $11.8M-39.4% | $19.4M-28.6% | $27.2M+601.1% | $3.9M-29.0% | $5.5M+4145.2% | -$135K-124.8% | $545K+4048.1% | -$14K-186.8% | $16K+7.9% | $15K |
| Retained Earnings | -$63.0M-25.7% | -$50.1M-24.4% | -$40.3M-29.9% | -$31.0M-48.2% | -$20.9M-121.2% | -$9.5M-96.8% | -$4.8M-82.3% | -$2.6M-794.2% | -$295K-390.2% | -$60K-97.3% | -$31K-99.8% | -$15K |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ARTL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$12.6M | -$8.5M-2.0% | -$8.3M-1.7% | -$8.2M-2.5% | -$8.0M-30.4% | -$6.1M-41.3% | -$4.3M-55.7% | -$2.8M-73.5% | -$1.6M-642.6% | -$217K | N/A | -$14K+11.6% | -$15K |
| Investing Cash Flow | N/A | -$62K-100.8% | $7.8M+121.5% | $3.5M+18.6% | $3.0M+186.0% | -$3.4M | $0+100.0% | -$1.5M-177496.2% | -$845 | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $14.8M | $6.9M+6031.3% | $112K-80.2% | $567K | $0-100.0% | $14.1M+612.4% | $2.0M-76.4% | $8.4M+503.4% | $1.4M+76.8% | $785K | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
ARTL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity | N/A | -343.9%-264.9pp | -79.0%-27.1pp | -52.0%-17.3pp | -34.6%+85.5pp | -120.1%-80.4pp | -39.8% | N/A | -43.1% | N/A | -95.9%+7.7pp | -103.6% |
| Return on Assets | -459.8%-250.7pp | -209.1%-137.9pp | -71.2%-21.9pp | -49.4%-16.1pp | -33.3%+73.1pp | -106.4%-72.9pp | -33.5% | N/A | -40.9% | N/A | -89.5%+14.1pp | -103.6% |
| Current Ratio | 0.17-1.3x | 1.44-7.1x | 8.51-9.9x | 18.36-5.6x | 23.96+19.3x | 4.66+0.3x | 4.35+3.6x | 0.75-18.8x | 19.51+19.3x | 0.21-9.6x | 9.79 | N/A |
| Debt-to-Equity | N/A | 0.64+0.5x | 0.11+0.1x | 0.050.0x | 0.04-0.1x | 0.13-0.1x | 0.19 | N/A | 0.05 | N/A | 0.11+0.1x | 0.00 |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$1.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.17), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Artelo Biosciences Inc Ranks
Frequently Asked Questions
Is Artelo Biosciences Inc profitable?
No, Artelo Biosciences Inc (ARTL) reported a net income of -$12.9M in fiscal year 2025.
What is Artelo Biosciences Inc's operating cash flow?
Artelo Biosciences Inc (ARTL) recorded an outflow of $8.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Artelo Biosciences Inc's total assets?
Artelo Biosciences Inc (ARTL) had $2.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Artelo Biosciences Inc spend on research and development?
Artelo Biosciences Inc (ARTL) invested $5.4M in research and development during fiscal year 2025.
What is Artelo Biosciences Inc's current ratio?
Artelo Biosciences Inc (ARTL) had a current ratio of 0.17 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Artelo Biosciences Inc's return on assets (ROA)?
Artelo Biosciences Inc (ARTL) had a return on assets of -459.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Artelo Biosciences Inc's cash runway?
Based on fiscal year 2025 data, Artelo Biosciences Inc (ARTL) had $600K in cash against an annual operating cash burn of $8.5M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Artelo Biosciences Inc's debt-to-equity ratio negative or not reported?
Artelo Biosciences Inc (ARTL) has negative shareholder equity of -$1.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Artelo Biosciences Inc's Piotroski F-Score?
Artelo Biosciences Inc (ARTL) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Artelo Biosciences Inc's earnings high quality?
Artelo Biosciences Inc (ARTL) reported a net loss of $12.9M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Artelo Biosciences Inc cover its interest payments?
Artelo Biosciences Inc (ARTL) reported an operating loss of $11.4M against $194K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.